# A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer

> **NCT01276548** · PHASE2 · COMPLETED · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 102 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC
- **DRUG:** Genexol® 175mg/m2 plus Carboplatin 5 AUC

## Key facts

- **NCT ID:** NCT01276548
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-09
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276548, "A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01276548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*